相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
Sabine Tejpar et al.
ONCOLOGIST (2010)
KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer
Roy D. Baynes et al.
AMERICAN JOURNAL OF THERAPEUTICS (2009)
A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
Justin M. Balko et al.
BMC CANCER (2009)
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2009)
Distinct BRAF (V600E) and KRAS Mutations in High Microsatellite Instability Sporadic Colorectal Cancer in African Americans
Krishan Kumar et al.
CLINICAL CANCER RESEARCH (2009)
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology
Milind Javle et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
Martin Pichler et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Claus-Henning Koehne et al.
ONCOLOGIST (2009)
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
Marc Peeters et al.
ONCOLOGIST (2009)
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
Jens Neumann et al.
PATHOLOGY RESEARCH AND PRACTICE (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
Hongdo Do et al.
BMC CANCER (2008)
Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population
Vanessa Deschoolmeester et al.
EUROPEAN JOURNAL OF CANCER (2008)
Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1
Yan Zhao et al.
GENE (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
K-ras mutation detection in colorectal cancer using the Pyrosequencing technique
Angela Poehlmann et al.
PATHOLOGY RESEARCH AND PRACTICE (2007)
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples:: KRAS codon 12 and 13 mutations in non-small cell lung cancer
Michael Krypuy et al.
BMC CANCER (2006)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer
V Deschoolmeester et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2006)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
Sensitive Sequencing method for KRAS mutation detection by pyrosequencing
S Ogino et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas:: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
V. Bazan et al.
ANNALS OF ONCOLOGY (2005)
Systematic review of genetic influences on the prognosis of colorectal cancer
S Anwar et al.
BRITISH JOURNAL OF SURGERY (2004)
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature
B Klump et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
F Graziano et al.
ANNALS OF ONCOLOGY (2003)
Effect of fixatives and tissue processing on the content and integrity of nucleic acids
M Srinivasan et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
Ras signaling pathway proteins as therapeutic targets
AA Adjei
CURRENT PHARMACEUTICAL DESIGN (2001)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
